PTO/SBI08A (04-07)
Approved for use through 09:30/2007. CMB 0865-0031
U.S. Patient and Trademark Office; U.S. DEPARTIMENT OF COMMERCE
Under the Paperwork Reduction Act of 1996, no psesons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	for form 1449/PTO			Complete if Known	
				Application Number	10/701,236
INFO	RMATION	DIS	CLOSURE	Filing Date	11-04-2003
STAT	LEMENT B.	Y AI	PPLICANT	First Named Inventor	Brenda F. Baker
				Art Unit	1635
	(Use as many she	ets as	necessary)	Examiner Name	Tracy Ann Vivlemore
Sheet	1	of	3	Attorney Docket Number	ISIS-5207

			U.S. PATENT I			
Examiner Initials *	Cite No.1	Number - Kind Code <sup>2</sup> (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
/T.V./	1	U.S. 4,720,483	01-19-1988	Jansz et al.		
	2	U.S. 4,757,141	07-12-1988	Fung et al.		
$\neg \vdash$	3	U.S. 5,082,934	01-21-1992	Saba et al.		
	4	U.S. 5,151,510	09-29-1992	Stec et al.		
$\neg$	5	U.S. 5,424,413	06-13-1995	Hogan et al.		
	6	U.S. 5,506,212	04-09-1996	Hoke et al.		
	7	U.S. 5,561,043	10-01-1996	Cantor et al.		
	8	U.S. 5,631,148	05-20-1997	Urdea		
	9	U.S. 5,639,873	06-17-1997	Barascut et al.		
	10	U.S. 5,719,271	02-17-1998	Cook et al.		
	11	U.S. 5,760,202	06-02-1998	Cook et al.		
$\neg$	12	U.S. 5,861,493	01-19-1999	Cook et al.		
	13	U.S. 5,891,684	04-06-1999	Usman et al.		
$\neg$	14	U.S. 5,955,443	09-21-1999	Bennett et al.		
	15	U.S. 5,998,203	12-07-1999	Matulic-Adamic et al.		
	16	U.S. 6,133,246	10-17-2000	McKay et al.		
	17	U.S. 6,210,892 B1	04-03-2001	Bennett et al.		
	18	U.S. 6,222,025 B1	04-24-2001	Cook et al.		
$\neg$	19	U.S. 6,262,036 B1	07-17-2001	Arnold, Jr. et al.		
$\neg$	20	U.S. 6,274,723 B1	08-14-2001	Nilsen		
	21	U.S. 6,506,559 B1	01-14-2003	Fire et al.		
	22	U.S. 6,818,759 B2	11-16-2004	Beigelman et al.		
	23	U.S. 7,022,828 B2	04-04-2006	McSwiggen		
	24	U.S. 2003/0125241 A1	07-03-2003	Wissenbach et al.		
	25	U.S. 2003/0139585 A1	07-24-2003	Uhlmann et al.		
$\neg$	26	U.S. 2003/0143732 A1	07-31-2003	Fosnaugh et al.		
$\neg$	27	U.S. 2003/0206887 A1	11-06-2003	Morrissey et al.		
	28	U.S. 2004/0029275 A1	02-12-2004	Brown et al.		
N/	29	U.S. 2004/0146867 A1	07-29-2004	Slattum et al.		
-v-	30	U.S. 2005/0142535 A1	06-30-2005	Damha et al.		

## FOREIGN PATENT DOCUMENTS

		Foreign Patent Document			Pages, Columns.	
Examiner Initials*	Cite No. <sup>1</sup>	Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Lines, Where Relevant Passages or Relevant Figures Appear	T°
/T.V./	31	EP 0 266 168 A2	05-04-1988	Amoco Corp.		
	32	WO 94/02498 A1	02-03-1994	Worcester Foundation for Experimental Biology		
	33	WO 96/07392 A2	03-14-1996	Hybridon, Inc.		
V	34	WO 02/44321 A2	06-06-2002	Max-Planck-Gesellschaft Wissenschaften E.V.		

Examiner	Date
Signature	Considered

PTO/SB08B (04.07)
Approved for use through 00.07.020 CMB 0651-031.

U.S. Patent and Trademark-Office, U.S. DEPARTMENT OF COMMERCE
Under the Papervork Reduction Act of 1995, no persons are required to respond to a collection of information unless constains a valid. ORIS control number

Substitute for form 1449/PTO	Complete if Known		
INFORMATION DISCLOSURE	Application Number	10/701,236	
	Filing Date	11-04-2003	
STATEMENT BY APPLICANT	First Named Inventor	Brenda F. Baker	
	Art Unit	1635	
(Use as many sheets as necessary)	Examiner Name	Tracy Ann Vivlemore	
Sheet 2 of 3	Attorney Docket Number	ISIS-5207	

		NON PATENT LITERATURE DOCUMENTS	_		
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/T.V./	35	ALAHARI, J. Pharmacology and Experimental Therapeutics, 1998, 286, 419-428			
100000	36	BEIGELMAN, J. Biol Chem, 1995, 270, 25702-25708			
	37	BERGER, Nucleic Acids Research, 1998, 26, 2473-2480			
+	38	BEVILACQUA, Biochemistry, 1996, 35, 9983-9994			
	39	BOUTLA, Current Biology, 2001, 11, 1776-1780			
1	40	COOK, Anti-Cancer Drug Design, 1991, 6, 585-607			
	41	DAMHA, J. Am. Chem. Soc., 120:12976-12977			
+	42	ELBASHIR, EMBO J., 2001, 20, 6877-6888			
+	43	HAMMOND, Nature, 2001, 2, 110-119			
+	44	KIMURA-HARADA, FEBS Lett., 1971, 13, 335-338;			
+	45	KOIZUMI, Nucleic Acids Research, 1989, 17, 7059-7071			
-	46	KUIMELIS, Nucleic Acids Res. 1994, 22, 1429-1436	$\vdash$		
+	47	LESNIK, Biochemistry, 1995, 34,10807-10815			
-	48	PARRISH, Molecular Cell, 2000, 6, 1077-1087			
1	49	PORTA, Biotechnology, 1995, 13, 161-164	+		

Examiner	Date	
Signature	Considered	

_							
	Substitute for form 1449/PTO				Complete if Known		
Ι.	INFORMATION DISCLOSURE			IIDE	Application Number	10/701,236	
	STATEMENT BY APPLICANT				Filing Date	11-04-2003	
	OTATEMENT BY ALL EIGANT				First Named Inventor	Brenda F. Baker	
					Art Unit	1635	
	(Use as many sheets as necessary)			s necessary)	Examiner Name	Tracy Ann Vivlemore	
Ĺ	Sheet	3	of	3	Attorney Docket Number	ISIS-5207	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1		
/T.V./	50	SHUMAN, J. Biol Chem, 1993, 268, 18943-18950	
	51	TOSQUELLAS, Nucleic Acids Research, 1998, 26, 2069-2074	
	52	TRACEWELL, Toxicology and Applied Pharmacology, 1995, 135, 179-184	
	53	TUSCHL, Molecular Interventions, 2002, 2, 158-167	
	54	VERONESE, II Farmaco, 1999, 54, 497-516	
	55	WILDS, Nucleic Acids Res., 2000, 28, 3625-3635	
	56	WU, J. Biol. Chem, 1998, 273, 2532-2542	
	57	YU, RNA, 1997, 324-331	
	58	YU, Bioorganic and Medicinal Chemistry, 1996, 4, 1685-1692	
$\bigvee$	59	Table listing related applications and office actions and rejections from those related applications	

Examiner Signature	/Tracy Vivlemore/	Date Considered	04/10/2008

Fxaminer

Date

\*EXAMINET: initial if reference considered, whether or not claims is in conformance with MPEP 699. Draw line through claims in not in conformance and not considered. Include copy of the communication to applicate and not considered. Include copy of the conformance with a conformance of the communication to applicate the conformance of the communication to applicate the communication and application. Conformation is required to data or retain a benefit by the public which is talk on the LSPTIO to process) an application. Conformation is required to data or retain a benefit by the public which is the file and by the LSPTIO to process) an application. Conformation and the communication and application formation to the CSPTIO to process) and application. Conformation of the communication and application formation to the CSPTIO to process and application formation of the communication and application formation of the communication and t FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance